TMB-H was found to predict the efficacy of immunotherapy for category I cancers types (such as CRC) where neoantigen load is related to CD8 T cell levels, while TMB-H was not found to predict response in category II cancer types where neoantigen load is not positively correlated with CD8 T-cell levels. This evidence concerns the gene CD8A and cancer.